Additionally, the 36-month beta value for BNTC is 0.39. There are mixed opinions on the stock, with 4 analysts rating it as a “buy,” 3 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for BNTC is 24.55M and currently, short sellers hold a 2.15% ratio of that float. The average trading volume of BNTC on July 09, 2025 was 102.68K shares.
BNTC) stock’s latest price update
Benitec Biopharma Inc (NASDAQ: BNTC)’s stock price has dropped by -6.45% in relation to previous closing price of $13.49. Nevertheless, the company has seen a gain of 7.86% in its stock price over the last five trading days. zacks.com reported 2025-06-16 that If you are looking for stocks that are well positioned to maintain their recent uptrend, Benitec Biopharma (BNTC) could be a great choice. It is one of the several stocks that passed through our “Recent Price Strength” screen.
BNTC’s Market Performance
Benitec Biopharma Inc (BNTC) has experienced a 7.86% rise in stock performance for the past week, with a -16.81% drop in the past month, and a 2.44% rise in the past quarter. The volatility ratio for the week is 8.07%, and the volatility levels for the past 30 days are at 9.39% for BNTC. The simple moving average for the past 20 days is -11.21% for BNTC’s stock, with a 3.93% simple moving average for the past 200 days.
Analysts’ Opinion of BNTC
H.C. Wainwright, on the other hand, stated in their research note that they expect to see BNTC reach a price target of $28. The rating they have provided for BNTC stocks is “Buy” according to the report published on December 16th, 2024.
Robert W. Baird gave a rating of “Outperform” to BNTC, setting the target price at $30 in the report published on December 13th of the previous year.
BNTC Trading at -11.39% from the 50-Day Moving Average
After a stumble in the market that brought BNTC to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -26.41% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at BNTC starting from SUVRETTA CAPITAL MANAGEMENT, L, who purchase 16,497 shares at the price of $12.83 back on Mar 31 ’25. After this action, SUVRETTA CAPITAL MANAGEMENT, L now owns 8,807,805 shares of Benitec Biopharma Inc, valued at $211,736 using the latest closing price.
SUVRETTA CAPITAL MANAGEMENT, L, the Director of Benitec Biopharma Inc, purchase 900,000 shares at $13.00 during a trade that took place back on Mar 26 ’25, which means that SUVRETTA CAPITAL MANAGEMENT, L is holding 8,793,245 shares at $11,700,000 based on the most recent closing price.
Stock Fundamentals for BNTC
The total capital return value is set at -0.31. Equity return is now at value -48.57, with -44.07 for asset returns.
Based on Benitec Biopharma Inc (BNTC), the company’s capital structure generated 0.01 points at debt to capital in total, while cash flow to debt ratio is standing at -19.47. The debt to equity ratio resting at 0.01. The interest coverage ratio of the stock is -36.62.
Currently, EBITDA for the company is -22.49 million with net debt to EBITDA at 3.43. The liquidity ratio also appears to be rather interesting for investors as it stands at 14.80.
Conclusion
In conclusion, Benitec Biopharma Inc (BNTC) has seen mixed performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
